Licensing & Partnerships 4 articles

Licensing & Partnerships examines agreements that transfer or share rights to biotechnology assets, platforms or development programs. Upfront payments, milestones, royalties, regional rights, co-development responsibilities and strategic rationale help explain how scientific programs are financed and commercialized. The category is distinct from Mergers & Acquisitions because ownership of an entire company is not the defining event; the focus is contractual access to assets, technology or capabilities.

Biotechnology News & Analysis

October 2, 2026, 1:34 PM · 3 mins read

Novo Nordisk grabs exclusive global rights to Hengrui’s oral GLP-1 GIP drug in $2.6B deal

Novo Nordisk will pay $2.6 billion for rights to Hengrui Pharma’s HRS-1596, a once-weekly oral GLP-1/GIP dual agonist now in Phase 1 trials for type 2 diabetes and weight management.

Biotechnology News & Analysis

October 2, 2026, 8:35 AM · 4 mins read

Novartis bets $7.8 billion on RNA drugs as Boehringer’s obesity hopes stumble

Novartis is putting up to $7.8 billion on the table for Abogen’s RNA therapies. Meanwhile, Boehringer Ingelheim and Zealand Pharma’s obesity drug failed to impress in a tough market.

Clinical Trials & Evidence

October 2, 2026, 7:32 AM · 4 mins read

Ever Supreme Bio Technology wins FDA orphan status for CAR001 as revenue surges

Ever Supreme Bio Technology has secured FDA Orphan Drug Designation for its off-the-shelf CAR-T therapy CAR001 in malignant glioma. The company also posted a third straight month of record revenue and is pushing global licensing plans.

Drug Discovery

October 2, 2026, 1:50 AM · 3 mins read

Novartis grabs exclusive global rights to Abogen's RNA drug in $7.8 billion deal

Novartis will pay up to $7.8 billion for exclusive access to Abogen's experimental RNA drug for autoimmune diseases, with options for more therapies. The deal starts with a $575 million upfront payment.